A-01 Registration at the conference venue Tuesday 14:00-18:00 |
A-02 Welcome reception Tuesday 18:30-21:30 |
B-01 Registration at the conference venue Wednesday 08:00-08:45 |
B-02 Welcome and Introduction Wednesday 08:45-09:00 |
B-03 Thierry Buclin Meeting clinicians' and patients' needs in the practice of therapeutic monitoring Wednesday 09:00-09:20 |
B-04 Catherine Sherwin Model-based Dose Individualization Approaches Using Biomarkers Wednesday 09:20-09:50 |
B-05 Ron Keizer Experiences in applied clinical pharmacometrics: challenges, recommendations, and research opportunities Wednesday 09:50-10:10 |
B-06 Coffee break, poster and software session I: posters in Group I (with poster numbers starting with I-) are accompanied by their presenter Wednesday 10:10-11:40 |
B-07 Maddalena Centanni A pharmacometric framework for dose individualisation of sunitinib in GIST Wednesday 11:40-12:00 |
B-08 Chloe Pasin Use of mathematical modeling for optimizing and adapting immunotherapy protocols in HIV-infected patients Wednesday 12:00-12:20 |
B-09 Mouna Akacha Background on estimands and why are they important? Wednesday 12:20-12:35 |
B-10 Michael Looby PMX perspective on Estimands Wednesday 12:35-12:50 |
B-11 Discussion on estimands Wednesday 12:50-13:00 |
B-12 Lunch Wednesday 13:00-14:30 |
B-13 Camille Vong Power assessment for hierarchical combination endpoints using joint modelling of repeated time-to-event and time-to-event models versus Finkelstein-Schoenfeld method Wednesday 14:30-14:50 |
B-14 Yixuan Zou A novel score test-based method for efficient covariate selection in population pharmacokinetic analysis Wednesday 14:50-15:10 |
B-15 Qing Xi Ooi Evaluation of assumptions underpinning pharmacometric models Wednesday 15:10-15:30 |
B-16 Mats Karlsson Extensive and automatic assumption assessment of pharmacometric models Wednesday 15:30-15:50 |
B-17 Tea break, poster and software session II: posters in Group II (with poster numbers starting with II-) are accompanied by their presenter Wednesday 15:50-17:20 |
B-18 Oskar Alskär An integrated glucose homeostasis model of glucose, insulin, C-peptide, GLP-1, GIP and glucagon in healthy subjects and patients with Type 2 diabetes Wednesday 17:20-17:40 |
B-19 Daniel Hill-McManus Application of a linked pharmacometric/pharmacoeconomic model to assess the impact of non-adherence: Application to the treatment of gout Wednesday 17:40-18:00 |
C-01 Simon Buatois A pharmacometric extension of MCP-MOD in dose finding studies Thursday 08:30-08:50 |
C-02 Benjamin Guiastrennec New dosing recommendations for anti-tuberculosis therapy in Indian children Thursday 08:50-09:10 |
C-03 Jurgen Langenhorst Cause-specific hazard models with markovian elements to quantify the fludarabine exposure-response relationship: from learning to confirming in allogeneic hematopoietic cell transplantation Thursday 09:10-09:30 |
C-04 Gustaf Wellhagen A bounded integer model for rating and composite scale data Thursday 09:30-09:50 |
C-05 Presentation of Lewis Sheiner student session awards Thursday 09:50-09:55 |
C-06 Coffee break, poster and software session III: posters in Group III (with poster numbers starting with III-) are accompanied by their presenter Thursday 09:55-11:30 |
C-07 Phyllis Chan Assessment of a model to correlate early tumor size response to overall survival in relapsed or refractory diffuse large B cell lymphoma patients Thursday 11:30-11:50 |
C-08 Rui Zhu Exposure-response (E-R)-based product-profile (PP)-driven clinical utility index (CUI) to support phase III dose selection in oncology Thursday 11:50-12:10 |
C-09 Zinnia Parra-Guillen A quantitative modelling framework to inform dose selection of Xentuzumab, a dual insulin-like growth factor-I/II neutralizing antibody in cancer patients Thursday 12:10-12:30 |
C-10 Announcement for ACoP9 (2018) Thursday 12:30-12:35 |
C-11 Lunch Thursday 12:35-14:10 |
C-12 Scott Pruitt Clinical Overview of Immunotherapy in Oncology Thursday 14:10-14:40 |
C-13 Benjamin Ribba Drug response variability and optimal dosing in immuno-oncology Thursday 14:40-15:10 |
C-14 Tea break, poster and software session IV: posters in Group IV (with poster numbers starting with IV-) are accompanied by their presenter Thursday 15:10-16:40 |
C-15 Rukmini Kumar Predicting response and identifying responders to combination cancer immunotherapy in melanoma using Quantitative Systems Pharmacology (QSP) models Thursday 16:40-17:00 |
C-16 Hanna Silber Baumann PKPD analysis of soluble CD25 to characterize the concentration-effect relationship observed following the administration of Cergutuzumab Amunaleukin, a targeted immunocytokine for cancer immunotherapy Thursday 17:00-17:20 |
C-17 Announcement for WCoP 2020 Thursday 17:20-17:25 |
C-18 Social event Thursday 18:30-01:30 |
D-01 David Ternant Population and Bayesian kinetic modelling of necrosis biomarkers to assess the effect of conditioning therapies on infarct size Friday 09:15-09:35 |
D-02 João Abrantes Integrated modelling of factor VIII activity kinetics, occurrence of bleeds and individual characteristics in haemophilia A patients using a full random effects modelling (FREM) approach Friday 09:35-09:55 |
D-03 Elin Boger A partial differential equation approach to inhalation PBPK modelling Friday 09:55-10:15 |
D-04 Chihiro Hasegawa Simplification of multi-scale systems models for data-driven analyses: what has progressed in these 5 years? Friday 10:15-10:35 |
D-05 Preview of PAGE2019 Friday 10:35-10:40 |
D-06 Coffee break Friday 10:40-11:20 |
D-07 DDMoRe Model Repository challenge – prize ceremony Friday 11:20-11:30 |
D-08 Sulav Duwal A multiscale systems pharmacology framework to predict drug-class specific prophylactic efficacy of antivirals against HIV Friday 11:30-11:50 |
D-09 Vincent Madelain Ebola viral dynamics in nonhuman primates: insights into virus immuno-pathogenesis and antiviral strategies Friday 11:50-12:10 |
D-10 Closing remarks Friday 12:10-12:20 |
D-11 Audience input for potential PAGE2018 topics Friday 12:20-12:35 |
I-01 Annika Schneider Physiologically based pharmacokinetic modeling – application for renal and hepatic impairment Wednesday 10:10-11:40 |
I-02 Johannes Schropp Characterization of bispecific antibodies and the ternary complex including an optimal dosing strategy Wednesday 10:10-11:40 |
I-03 Pascal Schulthess Frequency-domain derived optimisation of cell cycle specific cancer treatment Wednesday 10:10-11:40 |
I-04 Bernard Sebastien Hypoglycemic risk kinetics modeling as patient achieving glucose control in insulin-naïve T2DM patients initiating glargine 300U/mL versus glargine 100U/mL Wednesday 10:10-11:40 |
I-05 Malte Selch Larsen Impact of trial designs, study conditions and statistical methods on the estimation of drug potency and power in clinical trials of haemophilia with inhibitors Wednesday 10:10-11:40 |
I-06 Jérémy Seurat Robust designs accounting for model uncertainty in longitudinal studies with binary outcomes Wednesday 10:10-11:40 |
I-07 Shringi Sharma A Joint Model to Evaluate the Relationship between Lymph Node Response and Progression-Free Survival in Chronic Lymphocytic Leukemia Wednesday 10:10-11:40 |
I-08 Dmitry Shchelokov A semi-mechanistic model of targeted therapy for melanoma Wednesday 10:10-11:40 |
I-09 Yucheng Sheng Item response theory modelling of motor scores to investigate feasibility of reducing proof-of-concept trial for Parkinson’s disease Wednesday 10:10-11:40 |
I-10 Christian Siebel Consensus on doxorubicin dosing in infants and children: pharmacokinetic simulations and Delphi process Wednesday 10:10-11:40 |
I-11 Alena Simalatsar Personalised delivery rate computation for intravenously administered anesthetic using Kalman filter Wednesday 10:10-11:40 |
I-12 Erik Sjögren Bridging physiologically based pharmacokinetic (PBPK) and population pharmacokinetic (PopPK) analyses in paediatric drug development: A case study based on intravenous esomeprazole Wednesday 10:10-11:40 |
I-13 Mike K Smith Implementing “best practice” in Pop PK modeling Wednesday 10:10-11:40 |
I-14 Tom Snowden A comparison of two model reduction methodologies for a QSP bone biology system with denosumab dosing. Wednesday 10:10-11:40 |
I-15 Victor Sokolov Evaluation of the utility and efficiency of MATLAB and R-based packages for the development of quantitative systems pharmacology models Wednesday 10:10-11:40 |
I-16 Eunjung Song Bayesian estimation of parameters in the pharmacokinetic model Wednesday 10:10-11:40 |
I-17 Felix Stader A population database for elderly to inform physiologically-based pharmacokinetic models considering anatomical, physiological and biological system parameters Wednesday 10:10-11:40 |
I-18 Konstantinos Stamatopoulos A Population based PBPK Modelling for the Prediction of Bile Salts Disposition within GI Luminal Fluids – Towards a Mechanistic Bile Salts Model Wednesday 10:10-11:40 |
I-19 Andrew Stein Guiding dose selection of monoclonal antibodies using a new parameter (AFTIR) for characterizing ligand binding systems Wednesday 10:10-11:40 |
I-20 Mark Stroh Customizing the distribution of a masked, tumor-activated antibody with quantitative systems pharmacology Wednesday 10:10-11:40 |
I-21 Sabine Stuebler Systems biology model of the mucosal immune system in the context of inflammatory bowel disease Wednesday 10:10-11:40 |
I-22 Claudia Suenderhauf The Basel Phenotyping Capsule as a tool for Quantifying Human metabolism in vivo – a tool to personalize physiological and semiphysiological Models Wednesday 10:10-11:40 |
I-23 Elin Svensson Meta-analysis of rifampicin exposure and mortality in three randomized controlled phase II tuberculosis meningitis trials Wednesday 10:10-11:40 |
I-24 Robin Svensson The value of model-based therapeutic drug monitoring in tuberculosis treatment – optimized target for rifampicin Wednesday 10:10-11:40 |
I-25 Elisa Tacconi Model-based analysis for the screening and ranking of compounds against Plasmodium Falciparum Wednesday 10:10-11:40 |
I-26 Chong Tang Population Pharmacokinetics of Tacrolimus in Pediatric Patients having undergone kidney, liver or bowel/liver transplantation. Wednesday 10:10-11:40 |
I-27 Lénaïg Tanneau Bedaquiline appears to antagonize its own main metabolite’s QTcF interval prolonging effect Wednesday 10:10-11:40 |
I-28 Sonya Chapman Dose Fractionation Study Design and PK/PD Model Analysis to Establish the Quantitative Pharmacology of Selective Aurora A Kinase Inhibition by Compound X and LY3295668 Wednesday 10:10-11:40 |
I-29 Nadia Terranova The CICIL tool: a Java-based user-friendly application for the analysis of individual tumor size lesion dynamics Wednesday 10:10-11:40 |
I-30 Adrien Tessier Population pharmacokinetics in adults and model-based extrapolation and dose selection in the paediatric DMD population for drug S48168/ARM210 Wednesday 10:10-11:40 |
I-31 Mita Thapar Population pharmacokinetic and exposure-lymphocyte analysis of FTY720 (Fingolimod/Gilenya) in pediatric patients with Multiple Sclerosis Wednesday 10:10-11:40 |
I-32 Pauline Themans Prediction of meropenem systemic and infection site exposure and open-loop control strategy for optimal drug dosing: a PBPK approach Wednesday 10:10-11:40 |
I-33 Tjokosela Tikiso TB/HIV co-treatment with superboosted lopinavir lowers abacavir concentrations in children Wednesday 10:10-11:40 |
I-34 Tom Haber DiffMEM: an open-source package for high-performance pharmacometric model estimation Wednesday 10:10-11:40 |
I-35 Elena Tosca In vitro-in vivo correlation (IVIVC) population modeling for the in silico bioequivalence of a long-acting release formulation of Progesterone. Wednesday 10:10-11:40 |
I-36 Kota Toshimoto Application of virtual clinical studies to predict the effect of inter-individual differences on the drug/metabolites exposures in the blood and target organs leading to different pharmacological and toxicological effect Wednesday 10:10-11:40 |
I-37 Pauline Traynard New library of time-to-event (TTE) models for the MonolixSuite and application to two experimental data sets Wednesday 10:10-11:40 |
I-38 Iñaki F. Trocóniz An immune quantitative framework for Hepatitis B viral infection Wednesday 10:10-11:40 |
I-39 Denise Feick Physiologically-based pharmacokinetic modeling of gemfibrozil drug-drug interactions with the CYP2C8 victim drugs repaglinide and pioglitazone Wednesday 10:10-11:40 |
I-40 Sami Ullah Population pharmacokinetic analysis of piperacillin in acute haemorrhagic stroke patients - a cerebral microdialysis study Wednesday 10:10-11:40 |
I-41 Chakradhara Rao Satyanarayana Uppugunduri Population pharmacokinetic model for individualized busulfan dosing in children: Annexation to the existing vast list of PopPK models for performance evaluation Wednesday 10:10-11:40 |
I-42 Piet van der Graaf Systems pharmacology modelling of the alternative pathway to study target suitability Wednesday 10:10-11:40 |
I-43 Louvina van der Laan Pharmacokinetics of intracellular stavudine-triphosphate in children after reduced-dose: can we improve stavudine’s safety profile? Wednesday 10:10-11:40 |
I-44 Michiel Van Esdonk Population pharmacokinetic/pharmacodynamic analysis of multiple nociceptive pain models following a single oral pregabalin dose administration to healthy subjects Wednesday 10:10-11:40 |
I-45 Erno van Schaick Simulations of the paliperidone pharmacokinetics of intramuscular long-acting injectable microsuspensions of paliperidone palmitate in rats using a mechanistic model Wednesday 10:10-11:40 |
I-46 Tamara van Steeg Development of a mathematical model to elucidate the cross-linking of GSK-057 and ADAs and binding to TNFR1 receptor – filling the gap between hypothesis and reality. Wednesday 10:10-11:40 |
I-47 Rob van Wijk Nanoscale blood sampling from zebrafish larvae for the estimation of distribution volume and absolute clearance Wednesday 10:10-11:40 |
I-48 Marc Vandemeulebroecke Graphical Principles Cheat Sheet Wednesday 10:10-11:40 |
I-49 Diego Vera Disease modelling of repeated acute attacks in an acute intermittent porphyria mouse model Wednesday 10:10-11:40 |
I-50 Swantje Völler Use of second-to-second physiological monitoring data for continuous evaluation of pharmacotherapy in preterm infants: an application to the respiratory stimulant doxapram Wednesday 10:10-11:40 |
I-51 Veronika Voronova Using a physiologically-based QSP model to simulate the effects of perturbations of the enterohepatic circulation of bile acids Wednesday 10:10-11:40 |
I-52 Johan Wallin Validation of Xenograft Dose Predictions for Clinical Efficacy in NSCLC Wednesday 10:10-11:40 |
I-53 Evan Wang Model-based assessment of QT interval correction methods Wednesday 10:10-11:40 |
I-54 Shijun Wang A comparison between nonlinear mixed effects and naïve pooled data methods in population PK model selection Wednesday 10:10-11:40 |
I-55 Roeland Wasmann Normal fat mass cannot be reliably estimated in typical pharmacokinetic studies Wednesday 10:10-11:40 |
I-56 Sebastian Weber Supporting drug development as a Bayesian in due time?! Wednesday 10:10-11:40 |
I-57 Sebastian Wicha Handling inter-occasion variability in model implementation for Bayesian forecasting: A comparison of methods and metrics. Wednesday 10:10-11:40 |
I-58 Mélanie Wilbaux Risk score based on survival multivariate analysis of baseline patients’ characteristics reduces variability in a PKPD model of tumor growth inhibition Wednesday 10:10-11:40 |
I-59 Justin Wilkins Population pharmacokinetic analysis of M7824 (MSB0011359C) in different cancer types Wednesday 10:10-11:40 |
I-60 Francis Williams Ojara A time-to-event analysis of paclitaxel-related peripheral neuropathy in patients with advanced non-small cell lung cancer receiving first line chemotherapy Wednesday 10:10-11:40 |
I-61 Dan Wright Identifying systematic bias in model predictions Wednesday 10:10-11:40 |
I-62 Liviawati Wu Population Pharmacokinetics and Dosing Simulation of JNJ-64155806 (AL-794) in Healthy Volunteers Wednesday 10:10-11:40 |
I-63 Gudrun Wuerthwein Population pharmacokinetics for PEGylated asparaginase Oncaspar® in children with ALL: differences between protocol parts and predictivity Wednesday 10:10-11:40 |
I-64 Xia Li Population pharmacokinetics of ciprofloxacin in critically ill patients-a covariate analysis Wednesday 10:10-11:40 |
I-65 Feifan Xie A model-based analysis of the kinetics of leukocytes in stage III ovarian cancer patients treated with neo-adjuvant chemotherapy, cytoreductive surgery and cisplatin-based intraperitoneal chemoperfusion Wednesday 10:10-11:40 |
I-66 James Yates Structural Identifiability for Mathematical Pharmacology: Models of myelosuppression Wednesday 10:10-11:40 |
I-67 Jinqiu Yin Optimizing treatment of cephalosporin-resistant pneumococcal meningitis Wednesday 10:10-11:40 |
I-68 Gunnar Yngman Linearization of full random effects modeling (FREM) for time-efficient automatic covariate assessment Wednesday 10:10-11:40 |
I-69 Jurij Aguiar Zdovc The expression of ABCB1 gene influences the PK of rivaroxaban – a PK/PD study in patients with the total hip or knee arthroplasty Wednesday 10:10-11:40 |
I-70 Nan Zhang Creation of Pharmacometric Framework to Evaluate Clinical Trial Data on Predictive Biomarkers Wednesday 10:10-11:40 |
I-71 Ying Zhang Exposure–Response Model and Development of a Shiny App of Subcutaneous C1-Inhibitor Concentrate to Estimate the Risk of Attacks in Patients with Hereditary Angioedema (HAE) Wednesday 10:10-11:40 |
I-72 Fan Zhang Structural and Practical Considerations in the Development of a Parent-metabolite Model Wednesday 10:10-11:40 |
I-73 Xiaoyan Zhang Population pharmacokinetic/pharmacodynamic modeling of plasma lyso-sphingomyelin response to enzyme replacement therapy olipudase alfa in patients with acid sphingomyelinase deficiency Wednesday 10:10-11:40 |
I-74 Li Zhang Mechanism-based Population PK/PD modeling of T lymphocytes Depletion and Repopulation Following Treatment with anti-CD52 Antibody GLD52 in Patients with Progressive Multiple Sclerosis Wednesday 10:10-11:40 |
I-75 Chenyan Zhao Quantification and prediction of the combined effect of minocycline and polymyxin B on multidrug-resistant Klebsiella pneumoniae Wednesday 10:10-11:40 |
I-76 Meng Zhaoling Real World Evidence and Model-informed Drug Development – an antidiabetic drug cardiovascular outcome case study Wednesday 10:10-11:40 |
I-77 Yi Zheng Effect of pregnancy on raltegravir free concentrations Wednesday 10:10-11:40 |
I-78 Xiao Zhu Application of pharmacometrics to stimulus response models to describe signalling profiles of the cannabinoid-1 receptor Wednesday 10:10-11:40 |
II-01 Esther Encinas Population pharmacokinetic modelling of the antihistamine bilastine in children within the context of a model informed paediatric drug development approach Wednesday 15:50-17:20 |
II-02 Aline Engbers Pharmacokinetics of ibuprofen in very preterm infants with patent ductus arteriosus Wednesday 15:50-17:20 |
II-03 Elvira Erhardt Bayesian knowledge integration for an in vitro–in vivo correlation (IVIVC) model Wednesday 15:50-17:20 |
II-04 Ruben Faelens Benefits of TDM in clinical management: a test case in infliximab for ulcerative colitis Wednesday 15:50-17:20 |
II-05 Dzhem Farandzha Tacrolimus Population Pharmacokinetic Analysis with Pmetrics in Infants after Liver Transplantation – preliminary data. Wednesday 15:50-17:20 |
II-06 Felix Held Bayesian hierarchical model of oscillatory cortisol response during drug intervention Wednesday 15:50-17:20 |
II-07 Kevin Feng Selecting in vitro dissolution tests using population pharmacokinetic modelling to help bioequivalence studies Wednesday 15:50-17:20 |
II-08 Yan Feng A Mixture Tumor Growth Dynamic (TGD) Model to Describe Differential Patterns of Longitudinal Tumor Response of Advanced Melanoma Patients Treated with Ipilimumab Wednesday 15:50-17:20 |
II-09 Fernandez Teruel Carlos Drug exposure / response model for neutropenia with lurbinectedin in cancer patients Wednesday 15:50-17:20 |
II-10 Martin Fink Informative study designs: The value of within-subject dose-escalation in the 'Espresso design' Wednesday 15:50-17:20 |
II-11 Chiara Fornari Development of a haematopoiesis systems pharmacology model for prediction of carboplatin induced bone marrow toxicity Wednesday 15:50-17:20 |
II-12 Jose Francis AADAC gene polymorphism and HIV infection affect the exposure of Rifapentine: a population pharmacokinetics analysis Wednesday 15:50-17:20 |
II-13 Thomas Frank LaTeX-based report writing: 10 years’ experience from Sanofi’s M&S group in Germany Wednesday 15:50-17:20 |
II-14 Sebastian Frechen A technical concept of automatic PBPK platform (re-)qualification in the Open Systems Pharmacology Suite (PK-Sim® and MoBi®) Wednesday 15:50-17:20 |
II-15 Matthias Frei Distinguishing myelosupressive response of a paclitaxel –radium-223 combination using a model-based analysis of an individual cross-over phase-Ib trial in cancer patients with bone lesions Wednesday 15:50-17:20 |
II-16 Svetlana Freiberga Understanding sources of variability: The variability attribution plot Wednesday 15:50-17:20 |
II-17 Nicolas Frey Bridging from Intravenous to Subcutaneous Formulation of Tocilizumab for Optimal Dose Regimens in Systemic Juvenile Idiopathic Arthritis Wednesday 15:50-17:20 |
II-18 Fiona G. Gao Prediction of human pharmacokinetics of subcutaneously administered depot formulation using MBPK model Wednesday 15:50-17:20 |
II-19 Silke Gastine Nonparametric Pharmacokinetic-Pharmacodynamic Modelling of Posaconazole Wednesday 15:50-17:20 |
II-20 Florence Gattacceca Pharmacokinetic-Pharmacodynamic (PKPD) model of Rilpivirine in HIV-1-infected patients treated with the single-tablet regimen rilpivirine/tenofovir/emtricitabine Wednesday 15:50-17:20 |
II-21 Wei Gao Viral Dynamics Model Predicts Clinical Efficacy in Hepatitis C Virus (HCV) Infected Patients Using Viral Kinetic Data from Phase 1 Studies Wednesday 15:50-17:20 |
II-22 Glenn Gauderat Reversing resistance to anticancer treatment supported by pharmacokinetic/pharmacodynamic modeling of tumor growth kinetics in xenograft mice Wednesday 15:50-17:20 |
II-23 Francois Gaudreault Model based Phase 2 Dose Selection of BIIB059 in Subjects with Systemic and Cutaneous Lupus Erythematosus (SLE and CLE) Wednesday 15:50-17:20 |
II-24 Kamunkhwala Gausi methodological characterization of qt/qtc in children with severe malaria anaemia receiving arthemether-lumefantrine preceded by quinine Wednesday 15:50-17:20 |
II-25 Anna Georgieva Kondic Integrated novel modelling framework for evaluating the efficacy and cost effectiveness of novel pharmaceutical agents in stroke prevention Wednesday 15:50-17:20 |
II-26 Eva Germovsek An exposure-response model relating nicotine plasma concentration to momentary craving across different nicotine replacement therapy formulations Wednesday 15:50-17:20 |
II-27 Anais Glatard Population pharmacokinetic model of amisulpride for individual dosing in psychiatric patients Wednesday 15:50-17:20 |
II-28 Nathalie Gobeau Model-based informed screening of antimalarial combinations Wednesday 15:50-17:20 |
II-29 Nele Goeyvaerts Population Pharmacokinetic/Pharmacodynamic of a Toll-Like-Receptor 7 (TLR7) Agonist that Induces IP-10 and ISG15 in Cynomolgus Monkeys Wednesday 15:50-17:20 |
II-30 Antonio Goncalves Modelling hepatitis B kinetics in mice treated by a novel TLR-7 agonist, alone or in combination with entecavir Wednesday 15:50-17:20 |
II-31 Ignacio Gonzalez-Garcia Exploration of different scenarios using a drug exposure-response model of Lurbinectedin Wednesday 15:50-17:20 |
II-32 Kosalaram Goteti Drug-disease model describing the effect of intraarticular injected sprifermin on cartilage thickness measured by magnetic resonance imaging in osteoarthritis patients Wednesday 15:50-17:20 |
II-33 Verena Gotta Modelling urea clearance in pediatric and young adult patients on chronic hemodialysis Wednesday 15:50-17:20 |
II-34 Sebastiaan Goulooze Supervised item response theory modelling improves prediction of iatrogenic withdrawal in children Wednesday 15:50-17:20 |
II-35 Silvia Grandoni Evaluating the inclusion of the particle size distribution in the lung dissolution model of a WB-PBPK model to describe the pharmacokinetics of inhaled polydisperse drugs. Wednesday 15:50-17:20 |
II-36 Hans Peter Grimm PK Projections for Therapeutic Proteins in Entry Into Human Studies: Roche pRED Experience From 2004 to 2016 Wednesday 15:50-17:20 |
II-37 Ana-Marija Grisic Towards a comprehensive PK/PD model of infliximab in inflammatory bowel diseases, with support of prior knowledge Wednesday 15:50-17:20 |
II-38 Felix Hammann Whole-body physiology pharmacokinetic modeling of flip-flop behavior of oral oxycodone solution in pediatric patients 5-16 years old Wednesday 15:50-17:20 |
II-39 Niklas Hartung A size- and location-structured model for pulmonary absorption, elimination and dissolution of an orally inhaled drug Wednesday 15:50-17:20 |
II-40 Emilie Hénin Individual therapeutic monitoring strategy of a factor IX concentrate (OCTAFIX ®) for prophylaxis in patients with haemophilia B, using population modelling approaches Wednesday 15:50-17:20 |
II-41 Andrea Henrich Mixed effects modeling of concentration-QT relationships: first experiences with the new white paper Wednesday 15:50-17:20 |
II-42 Eef Hoeben Modelling the Transfer of Sildenafil Across the Placenta with Data of an Ex-Vivo Human Placenta Perfusion Experiment Wednesday 15:50-17:20 |
II-43 Nick Holford Using Biomarkers to Predict the Target Dose of Warfarin and Linezolid Wednesday 15:50-17:20 |
II-44 Richard Hooijmaijers ShinyMixR: A project-centric R/Shiny run management tool for nlmixr Wednesday 15:50-17:20 |
II-45 Andrew Hooker Computation of the geometric mean and variance of the AUC using polynomial chaos Wednesday 15:50-17:20 |
II-46 Joy Hsu Population Pharmacokinetic and Exposure-Efficacy/Safety Analyses for the Confirmation of Alectinib 600 mg BID Dose Regimen in the Global ALK Inhibitor-Naïve Population Wednesday 15:50-17:20 |
II-47 Wilhelm Huisinga Cell-level based tumor cPBPK model to study mAb distribution within solid tumors and implications for efficacious treatment Wednesday 15:50-17:20 |
II-48 Hwi-yeol Yun Accurate and Precise Prediction of in-vivo hepatic clearance for drug with low KM Wednesday 15:50-17:20 |
II-49 Moustafa M. A. Ibrahim Model-based post-processing of CWRES for assessment of prediction bias Wednesday 15:50-17:20 |
II-50 Ibrahim Ince A Population Physiologically-Based Pharmacokinetic Model for prediction of pharmacokinetics of small molecule drugs in healthy Japanese adults: Bridging PBPK from Caucasian to Japanese ethnicity Wednesday 15:50-17:20 |
II-51 Mohamed Ismail An open source software solution for automating pharmacokinetic/pharmacodynamic model selection Wednesday 15:50-17:20 |
II-52 Julie Janssen Semi-physiological Pharmacokinetics of Bortezomib in Pediatric Patients with Acute Lymphoblastic Leukemia Wednesday 15:50-17:20 |
II-53 David Janzén Estimating absolute bioavailability in population models despite lacking IV data Wednesday 15:50-17:20 |
II-54 Petra Jauslin Population Pharmacokinetic Analysis of Tildrakizumab, an Anti-IL-23 Antibody, in Healthy Volunteers and Subjects with Psoriasis Wednesday 15:50-17:20 |
II-55 Garrit Jentsch A repeated time-to-event model is superior to a count regression analysis in linking FVIII activity to bleeding events in prophylactically treated patients with severe haemophilia A Wednesday 15:50-17:20 |
II-56 Jane Knöchel Focusing on the essential dynamics of systems pharmacology models by exploiting an input-response characterisation Wednesday 15:50-17:20 |
II-57 Martin Johnson Artificial neural networks can facilitate the analysis and prediction of longitudinal tumour size data: an example from a non-small cell lung cancer phase III study Wednesday 15:50-17:20 |
II-58 Koen Jolling Population pharmacokinetic modelling of CHF6001 following dry powder inhalation in healthy volunteers. Wednesday 15:50-17:20 |
II-59 Fredrik Jonsson Exposure-Response Modeling of Emicizumab for the Prophylaxis of Bleeding in Hemophilia A Patients Wednesday 15:50-17:20 |
II-60 Niclas Jonsson Increasing the efficiency of the covariate search algorithm in the SCM Wednesday 15:50-17:20 |
II-61 Siv Jonsson Sample size for detection of drug effect using item level and total score models for Unified Parkinson’s Disease Rating Scale data Wednesday 15:50-17:20 |
II-62 Felix Jost Gauss-Newton algorithm for parameter estimation of nonlinear mixed-effects models Wednesday 15:50-17:20 |
II-63 Astrid Jullion Dosing Regimen selection supported by population PKPD model of thrombocytopenia Wednesday 15:50-17:20 |
II-64 Yunseob Jung A population pharmacokinetic model of methotrexate in Korean people Wednesday 15:50-17:20 |
II-65 Fabian Jung Evaluation of release techniques for nanocarriers on the basis of IVIVC-PBPK modeling Wednesday 15:50-17:20 |
II-66 Tobias Kanacher Development of a whole body physiologically-based pharmacokinetic (PBPK) model for inhaled salmeterol to predict interactions with CYP3A4 inhibitors Wednesday 15:50-17:20 |
II-67 Iasonas Kapralos Population Pharmacokinetics of Anidulafungin in ICU patients Wednesday 15:50-17:20 |
II-68 Eleni Karatza Mathematical modeling of gastric emptying: a joint model for losartan and its active metabolite EXP-3174 Wednesday 15:50-17:20 |
II-69 Yuri Kheifetz Integral individualized model of hematopoiesis explains and predicts joint dynamics of thrombocytes, granulocytes and lymphocytes under different chemotherapeutic and adjuvant treatments scenarios Wednesday 15:50-17:20 |
II-70 Yun Kim A population pharmacokinetic analysis of voriconazole according to CYP2C19 phenotype in healthy subjects and patients Wednesday 15:50-17:20 |
II-71 Yu Kyong Kim A Prospective Population Pharmacokinetic Study for Recommendation of Prophylactic Fluconazole Dosage Regimen in Preterm Infants Wednesday 15:50-17:20 |
II-72 Hyungsub Kim Pharmacokinetic and pharmacodynamic modeling of 10% intravenous immunoglobulin and glucocorticoids for adult patients with immune thrombocytopenia Wednesday 15:50-17:20 |
II-73 Anne Kümmel Building predictive longitudinal PKPD models of antimalarial combinations with Phase 2b data Wednesday 15:50-17:20 |
II-74 Franziska Isabelle Kluwe Joint model for the characterisation of cefuroxime pharmacokinetics in synovial fluid, interstitial fluid of muscle tissue and plasma Wednesday 15:50-17:20 |
II-75 Wojciech Krzyzanski Implementation of delay differential equations in NONMEM Wednesday 15:50-17:20 |
II-76 Gilbert Koch Characterization of postnatal sodium fluctuation in very preterm neonates Wednesday 15:50-17:20 |
II-77 Catherine Sherwin Tacrolimus population pharmacokinetics in paediatric kidney transplant patients Wednesday 15:50-17:20 |
III-01 Angela Äbelö Population concentration-QT-modelling of CHF6001 following dry powder inhalation in healthy volunteers. Thursday 09:55-11:30 |
III-02 Nada Abla Geiser Development of PBPK drug models to support antimalarial combination strategy Thursday 09:55-11:30 |
III-03 Amais Ahmad Evaluation of Prediction Performance of In Silico PBPK models of oral drug absorption Thursday 09:55-11:30 |
III-04 Jae Eun Ahn Pharmacokinetic/Pharmacodynamic effects of PF-06648671, a novel gamma secretase modulator following single and multiple dose administration in healthy volunteers Thursday 09:55-11:30 |
III-05 Yasunori Aoki Second order Taylor expansion of likelihood-based models for fast covariate and random effect model building Thursday 09:55-11:30 |
III-06 Usman Arshad Development of visual predictive checks accounting for multimodal parameter distributions in mixture models Thursday 09:55-11:30 |
III-07 Muhammad Waqar Ashraf A semi-PBPK model to describe the mechanism based drug-drug interaction between S-ketamine and ticlopidine in healthy human volunteers. Thursday 09:55-11:30 |
III-08 Magnus Åstrand Longitudinal pharmacometric modelling of serum potassium lowering effect of sodium zirconium cyclosilicate in patients with hyperkalemia Thursday 09:55-11:30 |
III-09 Linda Aulin Quantitative modelling of procalcitonin as a treatment response biomarker in sepsis Thursday 09:55-11:30 |
III-10 Geraldine Celliere Development of guidelines to efficiently choose and diagnose target-mediated drug disposition models Thursday 09:55-11:30 |
III-11 Vanessa Baier Developing a physiology-based model of bile acid metabolism in men Thursday 09:55-11:30 |
III-12 Pavel Balazki A Physiologically-based Quantitative Systems Pharmacology model of the incretin hormones GLP-1 and GIP Thursday 09:55-11:30 |
III-13 Belén Pérez Solans Mechanistic model of the myeloablative effects of treosulfan and busulfan in pediatric patients undergoing bone marrow transplant Thursday 09:55-11:30 |
III-14 Irina Baltcheva Model-based dose selection for the Phase 2b study of ianalumab in primary Sjögren's Syndrome Thursday 09:55-11:30 |
III-15 Guillaume Baneyx Target-mediated drug disposition modeling of lacnotuzumab in healthy volunteers and patients with advanced malignancies and triple negative breast cancer. Thursday 09:55-11:30 |
III-16 Catalina Barceló Modelling waist-hip ratio increase in HIV-infected individuals starting antiretroviral therapy Thursday 09:55-11:30 |
III-17 Christian Bartels ggPMX: a toolbox to easily generate a comprehensive set of model diagnostic plots for population models Thursday 09:55-11:30 |
III-18 Roberta Bartolucci A PBPK model for the study of Azathioprine pharmacokinetics in rats and prediction in humans Thursday 09:55-11:30 |
III-19 Carla Bastida Fernández PK/PD of the individual components of composite indexes variables used for disease activity assessment in rheumatoid arthritis patients on tocilizumab treatment. Thursday 09:55-11:30 |
III-20 Ryan Beechinor A population pharmacokinetic study of high dose methotrexate treatment in infants with acute lymphoblastic leukemia: The importance of modeling inter-occasion variability across treatment cycles Thursday 09:55-11:30 |
III-21 Amina Bensalem Concentration-effect relationships of therapeutic monoclonal antibody rituximab in rheumatoid arthritis. Thursday 09:55-11:30 |
III-22 Agathe Béranger Piperacillin dosing regimen optimization in critically ill children according to different creatinine clearances Thursday 09:55-11:30 |
III-23 Agnieszka Bienert Pharmacokinetics of dexmedetomidine in elderly patients undergoing sedation after abdominal aortic surgery. Thursday 09:55-11:30 |
III-24 Robert Bies Pharmacokinetic-pharmacodynamic modelling of MK-2048 in ex vivo cervical tissue Thursday 09:55-11:30 |
III-25 Henrik Bjugård Nyberg A pediatric population pharmacokinetic model for ethionamide in South African children treated for drug-susceptible or drug-resistant tuberculosis. Thursday 09:55-11:30 |
III-26 Alessandro Boianelli A quantitative systems pharmacology model for understanding the role of dietary fructose metabolism in NAFLD Thursday 09:55-11:30 |
III-27 Charlotte Bon Capacity limits of ASGPR mediated liver targeting Thursday 09:55-11:30 |
III-28 Rolien Bosch A novel integrated QSP model of in vivo human glucose regulation to support development of a glucagon/GLP-1 dual agonist. Thursday 09:55-11:30 |
III-29 Ari Brekkan Viggosson Characterization of anti-drug antibodies using a bivariate mixed hidden Markov model Thursday 09:55-11:30 |
III-30 Philippine Eloy Genetics of nevirapine and anti-tuberculosis drugs pharmacokinetics interaction in HIV-tuberculosis co-infected patients in Mozambique Thursday 09:55-11:30 |
III-31 Hannah Britz Physiologically-based pharmacokinetic (PBPK) modeling of the strong CYP1A2 inhibitor fluvoxamine Thursday 09:55-11:30 |
III-32 Astrid Broeker An integrated pharmacometric dialysis model to evaluate the pharmacokinetic impact of renal replacement therapy Thursday 09:55-11:30 |
III-33 Jantine Brussee Dose Individualization of CYP3A Substrates in Children: Characterization of Maturation of Intestinal and Hepatic CYP3A Activity in Children to Predict First-pass and Systemic CYP3A-mediated Metabolism Thursday 09:55-11:30 |
III-34 Thierry Buclin Closed-loop control for propofol administration during anesthesia based on real-time concentration measurement: a simulation study Thursday 09:55-11:30 |
III-35 Wonkyung Byon Apixaban for treatment of venous thromboembolism (VTEtx): Use of Model-Based Meta-Analysis (MBMA) to support Phase 3 dose selection and beyond Thursday 09:55-11:30 |
III-36 Tim Cardilin Modeling of radiation therapy and radiosensitizing agents in tumor xenografts Thursday 09:55-11:30 |
III-37 Evelina Cardoso Population pharmacokinetic analysis of erlotinib in cancer patients affected by NSCLC Thursday 09:55-11:30 |
III-38 Marc Cerou HAM-D score analysis of patients under placebo with major depressive disorder using item response theory Thursday 09:55-11:30 |
III-39 Blesson Chacko Covariate effects on competing events: a simulation study comparing approaches Thursday 09:55-11:30 |
III-40 Dong Woo Chae Predictive Modeling of PCA Effect on Postoperative Pain Management Thursday 09:55-11:30 |
III-41 Anne Chain Extension of population pharmacokinetic analysis of pembrolizumab to paediatric patients patients with classical Hodgkin lymphoma Thursday 09:55-11:30 |
III-42 Pascal Chanu Pediatric plans optimization of C.E.R.A. (Continuous Erythropoietin Receptor Activator): clinical evidence obtained through a model-based integration of multisource data Thursday 09:55-11:30 |
III-43 Estelle Chasseloup Generation and Application of Avatars (Digital Twins) in Pharmacometric Modelling Thursday 09:55-11:30 |
III-44 Jonathan Chauvin COSSAC (COnditional Sampling use for Stepwise Approach based on Correlation tests) method for covariate search Thursday 09:55-11:30 |
III-45 Chee Ng Novel Multilevel Parallel Expectation Maximization (MPEM) Estimation Methods for Population Quantitative Pharmacology Analysis Thursday 09:55-11:30 |
III-46 Wenjun Chen Modeling the antitumor efficacy and pharmacokinetic/pharmacodynamic interaction between docetaxel and cabozantinib in human prostate cancer xenograft mouse models Thursday 09:55-11:30 |
III-47 Mohammed Cherkaoui Rbati A Liver Model for Chemoprotection Against Malaria Thursday 09:55-11:30 |
III-48 Manoranjenni Chetty Antidepressants, anxiolytics and statins: prediction of exposure changes due to aging Thursday 09:55-11:30 |
III-49 S. Y. Amy Cheung Challenges and opportunities in the development of medical therapies for paediatric populations and the role of extrapolation Thursday 09:55-11:30 |
III-50 Maxwell Chirehwa Correlates of tuberculosis treatment outcomes: application of regression trees and pharmacodynamic modelling techniques Thursday 09:55-11:30 |
III-51 Jason Chittenden PMDatR: A Pharmacometric Data Manipulation Package for R Thursday 09:55-11:30 |
III-52 Young-Kyung Choi Population pharmacokinetics of cycloserine in patients with multidrug-resistant tuberculosis Thursday 09:55-11:30 |
III-53 Francois Combes Modeling and Simulation Approach of Everolimus PK/PD Toward Completing a Pediatric Development Thursday 09:55-11:30 |
III-54 Valerie Cosson Population PKPD modeling of RO7046015 (PRX002/RG7935), an Anti--Synuclein Monoclonal Antibody for the treatment of Parkinson’s Disease Thursday 09:55-11:30 |
III-55 Perrine Courlet Comparison of escitalopram pharmacokinetics in HIV infected individuals with an uninfected psychiatric cohort Thursday 09:55-11:30 |
III-56 Vincent Croixmarie Use of a multivariate distribution to simulate severe renal impaired patients Thursday 09:55-11:30 |
III-57 Ailing Cui Quantitative Predictive Models for the Degree of Disability After Acute Ischemic Stroke Thursday 09:55-11:30 |
III-59 André Dallmann Characterization of paracetamol hepatotoxicity during pregnancy through physiologically-based pharmacokinetic modeling Thursday 09:55-11:30 |
III-60 Daniel Kaschek An Integrated R-Based Framework for Model Development in Health Economics Thursday 09:55-11:30 |
III-61 Kim Dao Evaluation of exposure to vancomycin in neonates under existing dosing regimens using a population pharmacokinetic approach Thursday 09:55-11:30 |
III-62 Olivier David A PKPD model describing the amyloid precursor protein (APP) derived peptides in subjects receiving CNP520, a BACE-1 inhibitor. Thursday 09:55-11:30 |
III-63 Nico de Jager Population pharmacokinetic modelling of factor VIII levels during perioperative dosing of Haemate® P (Humate P) in patients diagnosed with von Willebrands Disease. Thursday 09:55-11:30 |
III-64 Giuseppe De Nicolao Analysis of muscular biopsy distributional data in Duchenne Muscular Dystrophy treatment: a population approach Thursday 09:55-11:30 |
III-65 Mailys De Sousa Mendes Mechanistic modelling of in-vitro bidirectional permeability studies and in vivo absorption of metoprolol Thursday 09:55-11:30 |
III-66 Elien De Thaye In vitro data supporting circulating CCCK18 as potential pharmacodynamic biomarker in ovarian cancer Thursday 09:55-11:30 |
III-67 Aurelia de Vries Schultink Therapeutic drug monitoring of endoxifen in ER-positive breast cancer patients: comparing data from clinical practice to model-based predictions. Thursday 09:55-11:30 |
III-68 Neel Deferm A Mechanistic Cellular Disposition Model of Bile Acid Handling in Sandwich-Cultured Human Hepatocytes Thursday 09:55-11:30 |
III-69 Oleg Demin Simulations of tau-targeted therapies using quantitative systems pharmacology model of tau pathology Thursday 09:55-11:30 |
III-70 Oleg Demin Jr Quantitative Systems Pharmacology Modeling of CAR-T Therapy and T Cell Engaging Bispecific Antibodies: B-cell Acute Lymphoblastic Leukemia Case Study Thursday 09:55-11:30 |
III-71 Aris Dokoumetzidis Population pharmacokinetics of teicoplanin in preterm and term neonates with late-onset sepsis Thursday 09:55-11:30 |
III-72 Artem Dolgun A functional, integrative R environment workflow for the development and use of quantitative systems pharmacology models Thursday 09:55-11:30 |
III-73 Anne-Gaelle Dosne Optimizing Biomarker-Based Dosing Algorithm for Erdafitinib through PK-PD Modeling and Simulations Thursday 09:55-11:30 |
III-74 Erwin Dreesen Development of a population pharmacokinetic and pharmacodynamic model to describe the effect of infliximab induction therapy on mucosal healing in patients with ulcerative colitis Thursday 09:55-11:30 |
III-75 Vincent Dubois Comparative attributes of a semimechanistic and an empirical population PK model for durvalumab, a fully human anti-PD-L1 monoclonal antibody Thursday 09:55-11:30 |
III-76 Miro Eigenmann Dynamic in vitro PKPD assessment to improve pharmacological response profiling of T-cell bispecifics Thursday 09:55-11:30 |
III-77 Salvatore D'Agate Development of a drug-disease model describing individual IPSS trajectories in BPH patients: Implication of disease progression and covariate factors on long term treatment response Thursday 09:55-11:30 |
IV-01 Brigitte Lacroix A quantitative framework integrating exposure, efficacy, receptor occupancy and tolerability to propose evidence-based dose regimens for padsevonil Thursday 15:10-16:40 |
IV-02 Shankar Lanke Population Pharmacokinetic Analyses of Tolvaptan in Subjects with Autosomal Dominant Polycystic Kidney Disease Thursday 15:10-16:40 |
IV-03 Christian Laveille Population pharmacokinetics of Rimeporide in healthy volunteers and children suffering from Duchenne Muscular Dystrophy (DMD) Thursday 15:10-16:40 |
IV-05 Robert Leary Automatic framework for bioequivalence studies from In Vitro test to In Vivo study design Thursday 15:10-16:40 |
IV-06 Woo Yul Lee A population pharmacodynamic model of combination antidepressant therapy in depression Thursday 15:10-16:40 |
IV-07 Quentin Leirens Clinical Trial Simulation of a Phase I Paediatric Oncology Study using Simulo Thursday 15:10-16:40 |
IV-08 Jennifer Leohr A Categorical Model of Sweet/Fat Preference Taste in Lean, Obese and Very Obese Subjects Thursday 15:10-16:40 |
IV-09 Giulia Lestini Two-step modelling approach of time to event and cognitive decline to inform Alzheimer’s disease prevention trials Thursday 15:10-16:40 |
IV-10 Leticia Arrington A Model Based Meta-Analysis (MBMA) to support development of medicines for treatment of DPN, PHN and Fibromyalgia. Thursday 15:10-16:40 |
IV-11 Hyeong-Seok Lim Pharmacokinetic and Pharmacodynamic Evaluation of Intravenous Levetiracetam in Children with Epilepsy Thursday 15:10-16:40 |
IV-12 Sihang Liu Population PK/PD analysis of ropinirole as a potential treatment for hyperprolactinemia Thursday 15:10-16:40 |
IV-13 Rasmus Jansson Löfmark Pharmacokinetic population modelling of a GLP1 beta cell targeting oligonucleotide Thursday 15:10-16:40 |
IV-14 Philip Lowe Ligelizumab Paediatric Investigation Plan: exposure-response analysis in adult chronic spontaneous urticaria with simulation-based design of adolescent dose-finding Thursday 15:10-16:40 |
IV-15 Qiang Lu Population pharmacokinetic analysis of dupilumab in adult and adolescent patients with asthma Thursday 15:10-16:40 |
IV-16 Rubin Lubomirov Population pharmacokinetic-based targeted exome sequencing (PopPK-TES) approach to assess the impact of genetic variants on pharmacokinetics of lurbinectedin in patients with advanced cancer Thursday 15:10-16:40 |
IV-17 Sreenath M Krishnan Accuracy in the estimation of the hazard in simultaneous and sequential estimation approaches of tumor size and overall survival (OS) modeling Thursday 15:10-16:40 |
IV-18 Lei Ma Efpeglenatide dose selection for a phase 3 study in type 2 diabetes mellitus (T2DM) patients: pharmacokinetics and pharmacodynamics (PK/PD) modeling, network meta-analysis and clinical trial simulation Thursday 15:10-16:40 |
IV-19 Matthias Machacek A Systems Pharmacology model of peripheral serotonin production proposing two different synthesis compartments with markedly different release rates into blood Thursday 15:10-16:40 |
IV-20 Paolo Magni Evaluation of software tools for Bayesian estimation on population models: an update based on current software versions Thursday 15:10-16:40 |
IV-21 Corinna Maier Improving model-based predictions of neutropenia using sequential data assimilation Thursday 15:10-16:40 |
IV-22 Victor Mangas-Sanjuan Defining level A IVIVC dissolution specifications based on individual in vitro dissolution profiles Thursday 15:10-16:40 |
IV-23 Jialin Mao PBPK modelling of drug-drug interactions driven by moderate CYP3A inducers Thursday 15:10-16:40 |
IV-24 Anita Mathias Joint population pharmacokinetic modelling of sofosbuvir and its metabolites (GS-566500, GS-331007) in Hepatitis C Virus (HCV)-infected adolescents receiving sofosbuvir or ledipasvir/sofosbuvir Thursday 15:10-16:40 |
IV-25 Tomomi Matsuura Clinical validation of a quantitative systems pharmacology (QSP) model for nerve-growth-factor (NGF) therapies Thursday 15:10-16:40 |
IV-26 Hannah Mayer A novel approach to estimate ontogenies for PBPK applications – From literature data to simulations Thursday 15:10-16:40 |
IV-27 Christophe Meille PKPD modeling of preclinical anti-tumor activity translates to first-in-human phase I study of MDM2 inhibitor HDM201 Thursday 15:10-16:40 |
IV-28 Nicola Melillo Variance based Global Sensitivity Analysis of a Physiological Absorption model for compounds in different BCS classes Thursday 15:10-16:40 |
IV-29 Johanna Melin Dapagliflozin pharmacokinetics is similar in adults with type 1 and type 2 diabetes mellitus Thursday 15:10-16:40 |
IV-30 Matilde Merino-Sanjuán Evaluation of the impact of undernourishment on the intestinal absorption of gefitinib in rats. Thursday 15:10-16:40 |
IV-31 Jonathan Mochel Modeling Primary Tumor Growth in a Xenograft Mouse Model of Non-Small Cell Lung Cancer Treated With Pemetrexed-Cisplatin and Bevacizumab Thursday 15:10-16:40 |
IV-32 Claudio Monteiro Sousa An in silico HBV model predicts viral response to the oral non-steroidal carboxylic acid FXR agonist EYP001a. Thursday 15:10-16:40 |
IV-33 Denise Morris Population Pharmacokinetic Modeling of Fremanezumab in Support of Phase 3 Development for Patients with Migraine Thursday 15:10-16:40 |
IV-34 Ricardo Nalda-Molina Population Pharmacokinetics of Hyperthermic Intraoperative Peritoneal Oxaliplatin in Wistar Rats Thursday 15:10-16:40 |
IV-35 Antonina Nikitich Immune Response Template for Quantitative Systems Pharmacology Modeling: Description of Co-inhibitory and Co-stimulatory Receptors Interaction Thursday 15:10-16:40 |
IV-36 Asbjørn Nøhr-Nielsen A review of fixed-dose combination approvals in the EU based on European public assessment reports (EPARs) Thursday 15:10-16:40 |
IV-37 Patrick Nolain PopkinR: a suite of Shiny applications focused on the pharmacometrics workflow Thursday 15:10-16:40 |
IV-38 Rikard Nordgren Faster methods for case deletion diagnostics: dOFV and linearized dOFV Thursday 15:10-16:40 |
IV-39 Ana Novakovic Simulation based assessment of flat dose regimen of an anti-PDL1 antibody: Case study of avelumab Thursday 15:10-16:40 |
IV-40 Eric Novik Stan: an open source probabilistic programming language for high-performance statistical computing Thursday 15:10-16:40 |
IV-41 Katharina Och A pharmacokinetic/pharmacodynamic model of cyclosporine A and its nephrotoxicity in patients after hematopoietic stem cell transplantation Thursday 15:10-16:40 |
IV-42 Chika Ogami Population pharmacokinetics of unbound daptomycin in hospital patients with Gram-positive infections Thursday 15:10-16:40 |
IV-43 Boram Ohk Population pharmacokinetics of sumatriptan in healthy korean subjects : sex differences Thursday 15:10-16:40 |
IV-44 Andrés Olivares-Morales Switching from immediate release to modified release can have an impact on intestinal drug-drug interactions: A PBPK simulation study using oxybutynin as a case example Thursday 15:10-16:40 |
IV-45 Erik Olofsen The definition and interpretation of utility functions Thursday 15:10-16:40 |
IV-46 Sean Oosterholt Implications of a model-based dosing algorithm for tacrolimus in paediatric kidney transplantation Thursday 15:10-16:40 |
IV-47 Taniya Paiboonvong Population Pharmacokinetics of Sitafloxacin in Thai Critically Ill Patients with Pneumonia Thursday 15:10-16:40 |
IV-48 Kwan Cheol Pak Physiologically based pharmacokinetic modeling of Herceptin and human pharmacokinetic prediction Thursday 15:10-16:40 |
IV-49 Semra Palic Exploring dose-dependent pharmacokinetics of miltefosine in pediatric visceral leishmaniasis patients from East Africa Thursday 15:10-16:40 |
IV-50 - - Efficacy and toxicity of intravenous salbutamol in children with acute severe asthma: a prospective clinical PKPD study Thursday 15:10-16:40 |
IV-51 Alice Panchaud Prediction of escitalopram exposure in infants through breastfeeding by modeling and simulation Thursday 15:10-16:40 |
IV-52 Navarat Panjasawatwong Population pharmacokinetics of rifampicin in Vietnamese Children with Tuberculous Meningitis Thursday 15:10-16:40 |
IV-53 Christophe Passot Therapeutic drug monitoring of eculizumab in atypical hemolytic uremic syndrome Thursday 15:10-16:40 |
IV-54 Dimple Patel Using real world data to assess SGLT2 Inhibitor cardiovascular benefit and impacts of patient population characteristics Thursday 15:10-16:40 |
IV-55 Henning Schmidt Reproducible submission-ready Word reports based on open source tools Thursday 15:10-16:40 |
IV-56 Violeta Balbas-Martinez Physiologically-Based Pharmacokinetic model for Ciprofloxacin in healthy children and approximation to children with complicated Urinary Tract Infection Thursday 15:10-16:40 |
IV-57 Cesar Pichardo QSP Modelling of Neurodegenerative Chronic Diseases and Brain Biomarkers: Adding the Effect of Ageing on Brain Volume Thursday 15:10-16:40 |
IV-58 Philippe Pierrillas PKPD modelling of EYP001a (a novel FXR agonist) in healthy volunteers and Hepatitis B patients Thursday 15:10-16:40 |
IV-59 Etienne Pigeolet Modeling of amyloid accumulation in subjects at risk of Alzheimer’s disease under BACE inhibition treatment. Thursday 15:10-16:40 |
IV-60 Nikhil Pillai Estimating parameters of chaotic systems: chaos synchronization combined with Nelder-Mead search Thursday 15:10-16:40 |
IV-61 Eduard Schmulenson A physiologically-based pharmacokinetic modeling approach to assess the impact of chronic kidney disease Thursday 15:10-16:40 |
IV-62 Teun Post An HCV nucleoside inhibitor MK-3682 minimal PBPK-PD model for application in hypothesis generation regarding metabolic pathways and perturbations under various conditions Thursday 15:10-16:40 |
IV-63 Manuel Prado-Velasco New approach based on physiological modelling to compute the bioavailability using the PhysPK biosimulation system Thursday 15:10-16:40 |
IV-64 Jens Przybilla Epigenetic modelling of DNA demethylation therapy in Acute Myeloid Leukemia Thursday 15:10-16:40 |
IV-65 Alicja Puszkiel Quantitative evaluation of the impact of CYP2D6 genetic polymorphisms on pharmacokinetics of tamoxifen and its metabolites in breast cancer patients Thursday 15:10-16:40 |
IV-66 Luis Quintairos Domenech Pharmacodynamic modelling of biomarkers in kidney transplantation: a transformed binary data population approach Thursday 15:10-16:40 |
IV-67 Hanne Refsgaard Steps Towards a Robust Generic Method for Deconvolution Directly on Pharmacokinetic Profiles Thursday 15:10-16:40 |
IV-68 Theo Reijmers Population PK Modelling of Treosulfan in Paediatric Allogeneic Transplant Patients Thursday 15:10-16:40 |
IV-69 François Riglet Multiple response modelling of mycophenolic acid pharmacokinetics in adult patients with transplanted kidneys by population approach Thursday 15:10-16:40 |
IV-70 Christer Rimmler Evaluating New Dosing Strategies for the Use of Cefuroxime in Perioperative Antibiotic Prophylaxis using PBPK Thursday 15:10-16:40 |
IV-71 Christelle Rodrigues A population pharmacokinetic model taking into account protein binding for the sustained-release granule formulation of valproic acid in children with epilepsy Thursday 15:10-16:40 |
IV-72 Leire Ruiz Cerdá External validation of Systems Pharmacology Models of the Coagulation Network with published data Thursday 15:10-16:40 |
IV-73 Yevgen Ryeznik Treatment allocation adaptive randomization methods in clinical trials with few individuals may influence model parameter estimation Thursday 15:10-16:40 |
IV-74 Oliver Sander Detecting and Analyzing 5x Sit-to-Stand Tests from Accelerometer Data Thursday 15:10-16:40 |
IV-75 Stein Schalkwijk Exploring Standard and Alternative Darunavir/Ritonavir Dosing Regimens for HIV-positive pregnant women using semi-mechanistic pharmacokinetic modeling Thursday 15:10-16:40 |
IV-76 Stephan Schaller Towards Predictions of Clinical Trial Outcomes: Combining PBPK and QSP within a Translational Diabetes Disease Platform Thursday 15:10-16:40 |
S-01 Kayla Andrews Data Repository to Enable Organization and Collaboration for Pharmacometric Analysis During entire meeting |
S-02 Sebastien Bihorel Data exploration libraries in KIWI During entire meeting |
S-03 Rikard Nordgren Perl speaks NONMEM (PsN) During entire meeting |
S-04 Tarjinder Sahota NMproject: Tidy, Reproducible, Script Based NONMEM projects in RStudio. A Step Toward Pharmacometric Industrialisation. During entire meeting |